Trius Therapeutics Company Profile (NASDAQ:TSRX)

About Trius Therapeutics (NASDAQ:TSRX)

Trius Therapeutics logoTrius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:TSRX
  • CUSIP: 89685K10
  • Web: N/A
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.47
  • P/E Growth: N/A
  • Dividend Yield: 1.0%

Frequently Asked Questions for Trius Therapeutics (NASDAQ:TSRX)

What is Trius Therapeutics' stock symbol?

Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX."

Who are some of Trius Therapeutics' key competitors?

How do I buy Trius Therapeutics stock?

Shares of Trius Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trius Therapeutics' stock price today?

One share of Trius Therapeutics stock can currently be purchased for approximately $13.63.

MarketBeat Community Rating for Trius Therapeutics (NASDAQ TSRX)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  99
MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Trius Therapeutics (NASDAQ:TSRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Trius Therapeutics (NASDAQ:TSRX)
No equities research coverage for this company has been tracked by


Earnings History for Trius Therapeutics (NASDAQ:TSRX)
Earnings by Quarter for Trius Therapeutics (NASDAQ:TSRX)
Earnings History by Quarter for Trius Therapeutics (NASDAQ TSRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2013Q212($0.33)($0.41)$3.71 million$1.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Trius Therapeutics (NASDAQ:TSRX)
Current Year EPS Consensus Estimate: $-1.44 EPS
Next Year EPS Consensus Estimate: $-1.44 EPS


Dividend History for Trius Therapeutics (NASDAQ:TSRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Trius Therapeutics (NASDAQ:TSRX)
Insider Trades by Quarter for Trius Therapeutics (NASDAQ:TSRX)
Insider Trades by Quarter for Trius Therapeutics (NASDAQ:TSRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/22/2013John FinnInsiderSell1,000$12.10$12,100.00View SEC Filing  
7/15/2013John FinnInsiderSell3,500$10.55$36,925.00View SEC Filing  
7/12/2013John FinnInsiderSell6,500$9.81$63,765.00View SEC Filing  
7/11/2013Michael MorneauCAOSell20,000$9.75$195,000.00View SEC Filing  
7/1/2013Philippe ProkocimerInsiderSell2,000$8.14$16,280.00View SEC Filing  
6/12/2013John FinnInsiderSell3,000$9.08$27,240.00View SEC Filing  
6/11/2013John FinnInsiderSell1,000$8.94$8,940.00View SEC Filing  
6/4/2013Ken BartizalInsiderSell2,000$7.90$15,800.00View SEC Filing  
6/3/2013Philippe ProkocimerInsiderSell2,000$7.75$15,500.00View SEC Filing  
5/24/2013Philippe ProkocimerInsiderSell12,000$7.93$95,160.00View SEC Filing  
5/14/2013Ken BartizalInsiderSell12,000$7.85$94,200.00View SEC Filing  
5/14/2013Michael MorneauCAOSell20,000$7.75$155,000.00View SEC Filing  
5/13/2013Philippe ProkocimerInsiderSell12,000$7.65$91,800.00View SEC Filing  
5/10/2013John FinnInsiderSell3,000$7.48$22,440.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Trius Therapeutics (NASDAQ:TSRX)
Latest Headlines for Trius Therapeutics (NASDAQ:TSRX)
DateHeadline logoIncyte Corporation (INCY) & Trius Therapeutics (TSRX) Head to Head Comparison - June 20 at 6:50 PM



Trius Therapeutics (TSRX) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff